CompanyDrug

Bayer’s Cevatertinib Wins Breakthrough Therapy Designation for HER2‑Mutant NSCLC

CompanyDeals

ImmuneOnco Terminates Axion Licenses, Regains Global Rights to IMM2510 and IMM27M

CompanyDrug

HutchMed’s Sovleplenib Meets Phase 3 Primary Endpoint in wAIHA, Targets NDA Filing

CompanyDeals

Structure Therapeutics Licenses GLP-1 Patents to Roche for $100 Million Upfront

CompanyDrug

Sichuan Biokin’s BL-B01D1 ADC Wins Priority Review for ESCC in China

CompanyDeals

Ikarovec and VectorBuilder Sign $1 Billion AAV Capsid Deal for AMD Gene Therapy

CompanyDrug

Zai Lab’s Repotrectinib Wins NMPA sNDA for NTRK Fusion-Positive Solid Tumors

CompanyDeals

Mabwell Partners with Sentonix on Neurodegenerative Disease Drug Discovery Alliance

CompanyDeals

Amgen Acquires Dark Blue Therapeutics for $840 Million to Expand AML Portfolio

CompanyDrug

BeOne’s Sonrotoclax Wins Conditional NMPA Approval for BCL-2 Inhibitor in CLL/SLL and MCL

CompanyDrug

XtalPi’s RTX-117 Wins NMPA IND for CMT Therapy

CompanyDrug

Ascentage’s PROTAC BTK Degrader APG-3288 Wins FDA IND for B-Cell Malignancies